Literature DB >> 11050056

Chronic ethanol increases adeno-associated viral transgene expression in rat liver via oxidant and NFkappaB-dependent mechanisms.

M D Wheeler1, H Kono, I Rusyn, G E Arteel, D McCarty, R J Samulski, R G Thurman.   

Abstract

Recombinant adeno-associated virus (rAAV) transduction is limited in vivo, yet can be enhanced by hydroxyurea, ultraviolet-irradiation, or adenovirus coinfection, possibly via mechanisms involving stress in the host cell. Because chronic ethanol induces oxidative stress, it was hypothesized that chronic ethanol would increase rAAV transduction in vivo. To test this hypothesis, rAAV encoding beta-galactosidase was given to Wistar rats that later received either ethanol diet or high-fat control diet via an enteral-feeding protocol for 3 weeks. Expression and activity of beta-galactosidase in the liver were increased nearly 5-fold by ethanol. The increase in transgene expression was inhibited by antioxidant diphenylene iodonium (DPI), which is consistent with the hypothesis that ethanol causes an increase in rAAV transduction via oxidative stress. Ethanol increased DNA synthesis only slightly; however, it increased the nuclear transcription factor kappaB (NFkappaB) 4-fold, a phenomenon also sensitive to DPI. Moreover, a 6-fold increase in rAAV transgene expression was observed in an acute ischemia-reperfusion model of oxidative stress. Transgene expression was transiently increased 24 hours after ischemia-reperfusion 3 days and 3 weeks after rAAV infection. Further, adenoviral expression of superoxide dismutase or IkappaBalpha superrepressor inhibited rAAV transgene expression caused by ischemia-reperfusion. Therefore, it is concluded that ethanol increases rAAV transgene expression via mechanisms dependent on oxidative stress, and NFkappaB likely through enhancement of cytomegaloviral (CMV) promoter elements. Alcoholic liver disease is an attractive target for gene therapy because consumption of ethanol could theoretically increase expression of therapeutic genes (e.g., superoxide dismutase). Moreover, this study has important implications for rAAV gene therapy and potential enhancement and regulation of transgene expression in liver.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050056     DOI: 10.1053/jhep.2000.19339

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Ethanol Alters APP Processing and Aggravates Alzheimer-Associated Phenotypes.

Authors:  Daochao Huang; Mengjiao Yu; Shou Yang; Dandan Lou; Weitao Zhou; Lingling Zheng; Zhe Wang; Fang Cai; Weihui Zhou; Tingyu Li; Weihong Song
Journal:  Mol Neurobiol       Date:  2017-08-10       Impact factor: 5.590

Review 2.  Animal models of alcoholic liver disease.

Authors:  Gavin E Arteel
Journal:  Dig Dis       Date:  2011-04-27       Impact factor: 2.404

Review 3.  Rodent models of alcoholic liver disease: of mice and men.

Authors:  Elizabeth Brandon-Warner; Laura W Schrum; C Max Schmidt; Iain H McKillop
Journal:  Alcohol       Date:  2012-09-07       Impact factor: 2.405

4.  Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo.

Authors:  Angela M Mitchell; Chengwen Li; R Jude Samulski
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

5.  Influence of Kupffer cells on hepatic signal transduction as demonstrated by second messengers and nuclear transcription factors.

Authors:  Hong Ding; Jie-An Huang; Jing Tong; Xin Yu; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

6.  Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model.

Authors:  Rachael S Watson Levings; Ted A Broome; Andrew D Smith; Brett L Rice; Eric P Gibbs; David A Myara; E Viktoria Hyddmark; Elham Nasri; Ali Zarezadeh; Padraic P Levings; Yuan Lu; Margaret E White; E Anthony Dacanay; Gregory B Foremny; Christopher H Evans; Alison J Morton; Mathew Winter; Michael J Dark; David M Nickerson; Patrick T Colahan; Steven C Ghivizzani
Journal:  Hum Gene Ther Clin Dev       Date:  2018-06       Impact factor: 5.032

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.